| abstract |
Provided is a blood test that can accurately predict cancer incidence or recurrence and guide and monitor the treatment intervention of the cancer. In one embodiment, the test includes obtaining a blood sample from a subject, capturing from the blood sample a circulating tumor DNA (ctDNA) using a first nanocomposition and a circulating tumor cell (CTC) using a second nanocomposition. The test further includes detecting at least a first nucleic acid biomarker from the ctDNA and detecting at least a CTC biomarker and at least a second nucleic acid biomarker from the CTC. |